March 14, 2023
Servier’s Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)
Servier’s Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)
March 9, 2023
Servier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier’s Onco-hematology Portfolio
Servier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier’s Onco-hematology Portfolio
February 24, 2023
Servier receives a positive CHMP opinion for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients
Servier receives a positive CHMP opinion for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients
February 2, 2023
Servier full year 2021/22 results confirm the transformation trajectory of the Group
Servier full year 2021/22 results confirm the transformation trajectory of the Group
January 17, 2023
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium
December 12, 2022
Real-World Analysis Suggests Pediatric-Inspired Regimens Lead to Higher Overall Survival in Adolescent and Young Adult Patients with Newly-Diagnosed Acute Lymphoblastic Leukemia
Real-World Analysis Suggests Pediatric-Inspired Regimens Lead to Higher Overall Survival in Adolescent and Young Adult Patients with Newly-Diagnosed Acute Lymphoblastic Leukemia
December 10, 2022
Servier Presents Patient Follow Up Data from the Phase 3 AGILE Study at ASH 2022
Servier Presents Patient Follow Up Data from the Phase 3 AGILE Study at ASH 2022
December 7, 2022
Servier Wins Reuters’ 2022 Patient Champion Award
Servier Wins Reuters’ 2022 Patient Champion Award
November 3, 2022
New Data at ASH 2022 Bolster Servier’s Leadership in Hematology Research
New Data at ASH 2022 Bolster Servier’s Leadership in Hematology Research
July 20, 2022
Servier Affirms Commitment to Cancer by Announcing the Opening of a Global R&D Center and Expanded Offices in Boston's Seaport
Servier Affirms Commitment to Cancer by Announcing the Opening of a Global R&D Center and Expanded Offices in Boston's Seaport
June 1, 2022
Servier to Showcase Growing Oncology Portfolio at the ASCO and EHA 2022 Annual Meetings
Servier to Showcase Growing Oncology Portfolio at the ASCO and EHA 2022 Annual Meetings
May 25, 2022
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

More from Servier

Research & Development

We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.

Learn More

Clinical Trials

We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.

Learn More

About Us

Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.

Learn More